New PET tracer targets cancer cells for sharper tumor imaging

NCT ID NCT07691775

Recruiting now Diagnosis Sponsor: Heron Neutron Medical Corp. Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests a new imaging agent called F18 FBPA, which is designed to light up cancer cells during a PET/CT scan. The agent targets a protein often found on solid tumors, potentially making tumors easier to see. Researchers want to find the best dose and timing for the scan, and check if it is safe. The study includes adults aged 18 to 80 with various solid tumors, such as lung, breast, or brain cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: F18 FBPA Injection
What this could lead to: If successful, this imaging method could help doctors detect and stage solid tumors more accurately, potentially guiding better treatment decisions.
What could go wrong: This is an early-phase study with only 30 participants, so results may not apply to all patients. The imaging agent may not work as well in some tumor types or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Show contact details

Locations

Taipei Veterans General Hsopital
RECRUITING

Taipei, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.